parapsoriasis

Large plaque parapsoriasis is usually a chronic condition that needs long-term treatment.

The parapsoriasis group, described and debated for nearly a century, has spawned a confusing nomenclature.

Other names for the condition include prereticulotic poikiloderma and atrophic parapsoriasis.

There are some authors who prefer to limit the term "parapsoriasis" to large- and small-plaque variants only.

Neoplasms can develop from parapsoriasis.

Xanthoerythrodermia perstans is a distinct variant of small-plaque parapsoriasis with lesions that are yellow in color.

In more recent times, after much discussion and growing consensus, parapsoriasis and its terminology has been revisited and re-examined often.

When the condition of the skin encompassed by these plaques worsens and becomes atrophic, it is typically considered retiform parapsoriasis.

Retiform parapsoriasis is a cutaneous condition, considered to be a type of large-plaque parapsoriasis.

Additionally, it may be considered a precursor or variant of the lymphomatous skin disorder mycosis fungoides, which is also associated with large plaque parapsoriasis.

Digitate dermatosis is a distinct variant of small-plaque parapsoriasis with lesions in the shape of a finger and distributed symmetrically on the flanks.

Large plaque parapsoriasis and dermatomyositis (an inflammatory disorder of the skin and muscle) are other common causes of PVA.

Small plaque parapsoriasis (also known as chronic superficial dermatitis) characteristically occurs with skin lesions that are round, oval, discrete patches or thin plaques, mainly on the trunk.

PVA also has common names that include parapsoriasis-related terminology (i.e. parapsoriasis variagata, or "variegated" parapsoriasis).

Brocq chose the term "parapsoriasis" to illustrate that the dermatoses placed in this group had or would have commonalities with psoriasiasis, including appearance and chronicity (lifelong or indefinite duration).

Parapsoriasis treatment consists primairly of Light therapy (more specifically PUVA therapy or UVB therapy) possibly in combination with Topical steroids.

PVA fits within this updated view of parapsoriasis as a syndrome often associated with large plaque parapsoriasis and, or including its variant form, retiform parapsoriasis.

PUVA is a psoralen + UVA treatment for eczema, psoriasis, graft-versus-host disease, vitiligo, mycosis fungoides, large-plaque parapsoriasis and cutaneous T-cell lymphoma.

Large plaque parapsoriasis (also known as "parapsoriasis en plaques") are skin lesions that may be included in the modern scheme of cutaneous conditions described as parapsoriasis.

Large-plaque parapsoriasis is a common associate of retiform parapsoriasis, can be accompanied by poikiloderma vasculare atrophicans, and can in rare occasions be a precursor to cutaneous T-cell lymphoma.

Brocq provided early, comprehensive descriptions of numerous skin disorders, including keratosis pilaris, parapsoriasis and a form of dermatitis called "Duhring-Brocq disease" (named with Louis Adolphus Duhring and sometimes referred to as dermatitis herpetiformis).

Newer thought on parapsoriasis, such as by Sutton (1956) all the way to that by Sehgal, et al. (2007) has cleared much of the confusion and has sparked increased understanding of parapsoriasis and its constituents.

This poorly designated grouping has led to confusion in establishing a nosology (a method of classifying diseases and disorders) that associated or distinguished these disorders, and through the years differing opinions and uses regarding parapsoriasis by both authors and physicians has caused further confusion.

PVA is believed to be a syndrome closely associated with large-plaque parapsoriasis and its cohort retiform parapsoriasis; including PVA, all three conditions fit within an updated view of the once ambiguous classification scheme known as parapsoriasis.